Medtronic’s OmniaSecure Lead Gains FDA Approval for Left Bundle Pacing, 4.7 Fr
The FDA approved Medtronic’s OmniaSecure defibrillation lead for left bundle branch area placement to enable conduction system pacing and LOT-CRT as the market’s smallest lead at 4.7 French. LEADR LBBAP trial results showed 100% defibrillation success at implant and a 2.1% three-month complication rate, backing its U.S. commercial launch.
1. FDA Approval Details
Medtronic received FDA approval to expand the OmniaSecure defibrillation lead indication for placement in the left bundle branch area. This approval allows the lead to deliver conduction system pacing and supports left bundle optimized cardiac resynchronization therapy (LOT-CRT) in patients who require both pacing and defibrillation.
2. Lead Features and Applications
The OmniaSecure lead is the smallest defibrillation lead on the market at 4.7 French and is approved for adults and adolescents aged 12 and up. Its lumenless design permits precise catheter-based delivery to the right ventricle or LBB area and compatibility with Medtronic Cobalt and Crome ICD and CRT-D devices, as well as LOT-CRT configurations.
3. Clinical Trial Outcomes
The global LEADR LBBAP trial demonstrated a 100% defibrillation success rate at implant and a 2.1% major complication rate at three months for LBB area placement. These outcomes underpin the lead’s January 2026 commercial launch in the U.S. and reinforce its reliability and safety for physiologic pacing.